Articles tagged "Genomic markers"

2016 American Transplant Congress
The First Impressions: A Study in Pre and Post-Implantation Renal Grafts for Early Detection Markers of Delayed Graft Function and Recovery.
S. Bontha,¹ L. Suh,¹ P. Dormish,¹ R. Gehrau,¹ E. Rhone,¹ L. Gallon,³ A. King,² C. Dumur,² D. Maluf,¹ V. Mas.¹
¹UVA, Charlottesville; ²VCU, Charlottesville; ³Northwestern University, Chicago.
Background: Delayed graft function (DGF) is mainly a consequence of ischemia and reperfusion injury (IRI) resulting in acute tubular necrosis. The degree of IRI is…
2016 American Transplant Congress
Non-Invasive Biomarkers for Graft Quality and Outcome Post-Liver Transplantation.
R. Gehrau, V. Mas, S. Bontha, D. Maluf.
Surgery, UVA, Charlottesville, VA.
Background: Graft quality is a determinant of graft function after liver transplantation (LT). This study aimed to evaluate graft molecular markers that correlate to peripheral…
2016 American Transplant Congress
DNA Methylation Patterns and Association with Graft Injury Severity Post Liver Transplantation.
R. Gehrau, S. Bontha, V. Mas, D. Maluf.
UVA, Charlottesville.
Background: Epigenetics modifications in the graft may influence injury severity and function post liver transplantation (LT). This study aimed to interrogate the effect of different…
2015 American Transplant Congress
Non-Invasive Panel of MicroRNAs Predict Long-Term Outcomes Post-Kidney Transplantation
J. Suh,¹ D. Maluf,¹ H. Cathro,² R. Gehrau,¹ I. McConnell,¹ K. Brayman,¹ C. Dumur,² V. Mas.¹
¹Surgery and Pathology, UVA, Charlottesville, VA; ²VCU, Richmond, VA.
Background. Currently available methods for evaluating kidney graft function post-transplantation (KT) are either ineffective or inaccurate (e.g., serum creatinine) or highly invasive (e.g., biopsies). We…
2015 American Transplant Congress
Plasma 4β-Hydroxycholesterol Measurement as a Potential Biomarker for CYP3A5 Activity in Informing Tacrolimus Dosing
T. Elnahhas,^1,2 E. de Jonge,⁴ T. Lee,² B. van Zelst,⁴ J. Popoola,³ R. Ramkhelawon,³ R. van Schaik,⁴ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St.George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom; ⁴Clinical Chemistry, Erasmus MC Rotterdam, Rotterdam, Netherlands.
Background—Recently, 4β-hydroxycholesterol (4β-OHC) has been shown to be an endogenous marker of P450 3A activity in clinical practice (Diczfalusy et al, 2011). 4β-OHC concentration increases…
2015 American Transplant Congress
APOL1 High-Risk Genotype in African American Live Kidney Donors Is Not Associated With Post-Donation Development of Hypertension and Kidney Disease
M. Doshi,¹ M. Goggines,² C. Winkler,³ J. Kopp.⁴
¹Wayne State University, Detroit, MI; ²Henry Ford Transplant Institute, Detroit, MI; ³NCI and Leidos, Frederick, MD; ⁴NIDDK, Bethseda, MD.
African Americans (AA) with two apolipoprotein L1 (APOL1) risk alleles have more kidney disease than compared to those with one or zero risk alleles. A…
2015 American Transplant Congress
Correlation of Longitudinal Gene-Expression Profiling Score to Cytomegalovirus Infection: Results from the Outcomes AlloMap® Registry
M. Kanwar,¹ J. Yee,² G. Ewald,³ S. Murali,¹ J. Teuteberg.⁴
¹Allegheny Singer Research Institute, Pittsburgh, PA; ²CareDx, Inc., Brisbane, CA; ³Washington University, St. Louis, MO; ⁴University of Pittsburgh Medical Center, Pittsburgh, PA.
Purpose: Cytomegalovirus (CMV) infection has been implicated in the pathogenesis of allograft rejection, which is reflected by high gene-expression profiling (GEP) scores. In the IMAGE…
2015 American Transplant Congress
Plasma Levels of Donor-Derived Cell-Free DNA Increase With Rejection and Often Decrease After Treatment in Organ Transplant Recipients
M. Grskovic,¹ J. Beausang,¹ D. Hiller,¹ R. Sit,¹ B. Christie,¹ J. Elechko,¹ R. Woodward,¹ J. Yee,¹ J. Kobashigawa.²
¹CareDx, Inc, Brisbane, CA; ²Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a potential biomarker of acute cellular rejection (ACR) in organ transplant recipients. dd-cfDNA levels in longitudinal plasma samples from…
2015 American Transplant Congress
Clinical Use of Gene-Expression Profiling to Monitor for Rejection After Cardiac Transplantation – Which Patients and When?
J. Teuteberg,¹ M. Shullo,¹ T. Wolf,² P. Prasad,² G. Ewald.³
¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²CareDx, Inc., Brisbane, CA; ³Washington University, St. Louis, MO.
Background: Gene-expression profiling (GEP), in place of endomyocardial biopsy, is increasing. GEP testing is intended for low-risk asymptomatic patients (pts); thus, the profile of pts…
2015 American Transplant Congress
Donor-Derived Cell-Free DNA Is Stable in Non-Rejecting Heart Transplant Recipients in the CARGO II Multicenter Trial
D. Hiller,¹ M. Grskovic,¹ J. Beausang,¹ R. Sit,¹ B. Christie,¹ J. Elechko,¹ R. Woodward,¹ J. Yee,¹ H. Eisen.²
¹CareDx, Inc, Brisbane, CA; ²Drexel University, University of Philadelphia, Philadelphia, PA.
Purpose: An elevated fraction of donor-derived cell-free DNA (dd-cfDNA) detected in the venous blood of recipients has been shown to be correlated to rejection of…